APA (7th ed.) Citation

CK, W., BY, S., IS, L., A, C., HAC, C., FC, T., . . . HF, T. (2026). Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 15(2), e039113. https://doi.org/10.1161/JAHA.124.039113

Chicago Style (17th ed.) Citation

CK, Wong, et al. "Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation." Journal of the American Heart Association 15, no. 2 (2026): e039113. https://doi.org/10.1161/JAHA.124.039113.

MLA (9th ed.) Citation

CK, Wong, et al. "Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation." Journal of the American Heart Association, vol. 15, no. 2, 2026, p. e039113, https://doi.org/10.1161/JAHA.124.039113.